Therapy Areas: Devices
Ortho Dermatologics Publishes Efficacy and Safety Data For Psoriasis Treatment Duobrii in Journal of the American Academy of Dermatology
11 April 2018 - - Ortho Dermatologics, a division of Laval, Quebec-based pharmaceutical and medical device company Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) has published positive results from two Phase 3, multicenter, randomized, double-blind clinical trials (Studies 1 and 2) to assess the safety and efficacy of Duobrii (halobetasol propionate and tazarotene) lotion in the treatment of plaque psoriasis in the Journal of the American Academy of Dermatology, the company said.
Studies 1 and 2, which enrolled a total of 418 patients, showed Duobrii was consistently more effective than vehicle in achieving treatment success, demonstrating statistically significant superiority by week four (in Study 1) and week two (in Study 2).
At week eight, 35.8% (Study 1) and 45.3% (Study 2) had achieved the primary efficacy outcome, compared to 7.0% and 12.5% on vehicle (both p


Related Headlines